Prevalence and Risk Factors of Helicobacter pylori-negative Peptic Ulcer
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 31 (1), 42-47
- https://doi.org/10.1097/00004836-200007000-00010
Abstract
Peptic ulcer disease (PUD) has been described in the absence of Helicobacter pylori (Hp) infection, suggesting that different factors are involved in its etiopathogenesis. We investigated prevalence and characteristics of Hp-negative (Hp-) PUD in an area of Northern Italy and calculated the rate of Hp-positive (Hp+) patients with PUD in whom Hp might be coincidental and not causal. Four hundred nine consecutive patients with endoscopically diagnosed PUD were enrolled in seven hospitals. Hp infection was assessed by rapid urease test and histologic examination. The attributable risk percentages in different age groups were calculated by appropriate formulas. Of 409 patients, 31 (7.6%) were Hp- (gastric, 8.3%; duodenal, 7.6%). Age, nonsteroidal antiinflammatory drug (NSAID) consumption, and complication rates were significantly higher in Hp-than Hp+ patients with duodenal ulcers (DUs). Of the Hp-patients with DU, 58% did not use NSAIDs. In patients with Hp+ DU, the attributable risk percentage for Hp infection in patients aged 60 years was 98%, 88%, and 66%, respectively. The prevalence of Hp- PUD was about 8%, mainly unrelated to any known etiologic factor. In about one-third of Hp+ patients with PUD aged over 60 years, Hp infection might be coincidental and not causal.Keywords
This publication has 12 references indexed in Scilit:
- Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycinAlimentary Pharmacology & Therapeutics, 2007
- Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.Gut, 1997
- Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group [see comments]Alimentary Pharmacology & Therapeutics, 1996
- Helicobacter pylori-Negative Duodenal and Pyloric Ulcer: Role of NSAIDsDigestion, 1996
- The development of atrophic gastritis—Helicobacter pylori and the effects of acid suppressive therapyAlimentary Pharmacology & Therapeutics, 1995
- Letter from the EditorsAlimentary Pharmacology & Therapeutics, 1995
- Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrenceAlimentary Pharmacology & Therapeutics, 1994
- A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.Gut, 1993
- Duodenal ulcers that are difficult to heal.BMJ, 1988
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988